Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 3,678 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 3,678 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.49, for a total value of $12,836.22. Following the sale, the insider now directly owns 139,090 shares of the company’s stock, valued at $485,424.10. The trade was a 2.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Amylyx Pharmaceuticals Trading Up 1.9 %

Shares of AMLX opened at $3.69 on Thursday. Amylyx Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $19.95. The stock has a market cap of $252.95 million, a P/E ratio of -0.97 and a beta of -0.54. The company has a 50-day moving average of $4.07 and a two-hundred day moving average of $3.66.

Analyst Ratings Changes

AMLX has been the subject of several recent research reports. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Bank of America upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the stock from $4.20 to $10.00 in a research note on Wednesday, October 23rd. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Amylyx Pharmaceuticals in a research note on Thursday, December 5th. Robert W. Baird raised shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $3.00 to $11.00 in a report on Monday, November 18th. Finally, Leerink Partners set a $4.00 price objective on Amylyx Pharmaceuticals and gave the company a “market perform” rating in a report on Friday, October 18th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. abrdn plc grew its holdings in Amylyx Pharmaceuticals by 1,567.9% during the 3rd quarter. abrdn plc now owns 1,972,242 shares of the company’s stock valued at $6,390,000 after buying an additional 1,853,995 shares during the last quarter. Alpha Wave Global LP purchased a new stake in shares of Amylyx Pharmaceuticals in the third quarter valued at $2,169,000. Walleye Capital LLC boosted its stake in shares of Amylyx Pharmaceuticals by 986.5% during the third quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock valued at $2,173,000 after acquiring an additional 608,874 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Amylyx Pharmaceuticals by 41.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 880,745 shares of the company’s stock worth $2,854,000 after purchasing an additional 258,818 shares in the last quarter. Finally, FMR LLC increased its position in Amylyx Pharmaceuticals by 292.0% during the 3rd quarter. FMR LLC now owns 221,001 shares of the company’s stock worth $716,000 after purchasing an additional 164,622 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.